Astrazeneca Pharma India, 506820, ASTRAZEN Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

21,996.25
190.05
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

21,459.55
0.36%
28.55

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

9.62
9.27
17.16

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
8.85
16.44

PAT CAGR (%)

10 Years
5 Years
3 Years

-
17.47
37.89

P:E (Median)

8 Years
5 Years
3 Years

107.33
107.86
98.89

P:BV (Average)

8 Years
5 Years
3 Years

20.08
20.11
20.19

EV:EBITDA (Average)

8 Years
5 Years
3 Years

61.75
65.23
64.34

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 64.6
P/E Ratio 135.89
Revenue 1296
EBITDA 184
Net Income 162
ROA 15.7
P/B Ratio 30.83
ROE 24.84
FCFF 49
FCFF Yield 0.25
Net Debt -501
BVPS 284.77

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var%
Net Sales 480.48 383.20 25.39% 440.29 305.79 43.98% 408.00 311.07 31.16% 387.52 295.47 31.15%
Expenses 394.11 333.81 18.06% 363.30 290.74 24.96% 355.46 258.31 37.61% 349.45 228.23 53.11%
EBITDA 86.37 49.39 74.87% 76.99 15.05 411.56% 52.54 52.76 -0.42% 38.07 67.24 -43.38%
EBIDTM 17.98% 12.89% 17.49% 4.92% 12.88% 16.96% 9.82% 22.76%
Other Income 16.15 8.66 86.49% 7.98 9.66 -17.39% 8.15 8.37 -2.63% 8.35 8.10 3.09%
Interest 0.68 -0.07 - 0.33 0.61 -45.90% 0.34 0.50 -32.00% 0.11 0.15 -26.67%
Depreciation 17.69 3.76 370.48% 9.07 3.70 145.14% 9.32 3.68 153.26% 3.91 3.79 3.17%
PBT 78.47 54.36 44.35% 42.02 20.40 105.98% 51.03 73.38 -30.46% -15.16 71.40 -
Tax 20.22 14.88 35.89% 11.17 4.60 142.83% 12.60 21.01 -40.03% -3.37 17.54 -
PAT 58.25 39.48 47.54% 30.85 15.80 95.25% 38.43 52.37 -26.62% -11.79 53.86 -
PATM 12.12% 10.30% 7.01% 5.17% 9.42% 16.84% -3.04% 18.23%
EPS 23.30 15.79 47.56% 12.34 6.32 95.25% 15.37 20.95 -26.63% -4.72 21.54 -

Description Dec 24 Dec 23 Var% Sep 24 Sep 23 Var% Jun 24 Jun 23 Var% Mar 24 Mar 23 Var%
Net Sales 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Expenses 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBITDA 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
EBIDTM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Other Income 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Interest 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Depreciation 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PBT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
Tax 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PAT 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0
PATM 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 1,716.29 1,295.53 1,002.97 805.60 813.56 831.81 728.29 571.00 543.71 563.73 517.07 Net Sales Growth 32.48% 29.17% 24.50% -0.98% -2.19% 14.21% 27.55% 5.02% -3.55% 9.02% Cost Of Goods Sold 963.01 590.03 355.22 305.28 287.30 299.97 226.73 178.21 171.18 194.81 194.23 Gross Profit 753.28 705.50 647.75 500.32 526.26 531.84 501.56 392.79 372.53 368.93 322.84 GP Margin 43.89% 54.46% 64.58% 62.11% 64.69% 63.94% 68.87% 68.79% 68.52% 65.44% 62.44% Total Expenditure 1,462.32 1,111.08 837.85 719.42 678.09 711.11 656.99 524.71 506.77 547.31 528.48 Power & Fuel Cost - 4.87 5.54 8.10 7.37 7.72 8.27 8.30 7.68 7.43 8.51 % Of Sales - 0.38% 0.55% 1.01% 0.91% 0.93% 1.14% 1.45% 1.41% 1.32% 1.65% Employee Cost - 241.45 259.10 230.21 219.54 216.70 197.40 150.39 162.04 169.35 159.84 % Of Sales - 18.64% 25.83% 28.58% 26.99% 26.05% 27.10% 26.34% 29.80% 30.04% 30.91% Manufacturing Exp. - 89.46 76.04 57.12 49.32 40.81 49.58 50.67 36.40 25.82 17.69 % Of Sales - 6.91% 7.58% 7.09% 6.06% 4.91% 6.81% 8.87% 6.69% 4.58% 3.42% General & Admin Exp. - 66.30 56.66 40.04 40.69 65.54 74.09 46.49 55.04 59.10 63.77 % Of Sales - 5.12% 5.65% 4.97% 5.00% 7.88% 10.17% 8.14% 10.12% 10.48% 12.33% Selling & Distn. Exp. - 97.48 71.57 62.09 55.94 65.13 88.18 81.07 62.56 84.65 77.77 % Of Sales - 7.52% 7.14% 7.71% 6.88% 7.83% 12.11% 14.20% 11.51% 15.02% 15.04% Miscellaneous Exp. - 21.49 13.72 16.58 17.93 15.24 12.74 9.58 11.87 6.16 77.77 % Of Sales - 1.66% 1.37% 2.06% 2.20% 1.83% 1.75% 1.68% 2.18% 1.09% 1.29% EBITDA 253.97 184.45 165.12 86.18 135.47 120.70 71.30 46.29 36.94 16.42 -11.41 EBITDA Margin 14.80% 14.24% 16.46% 10.70% 16.65% 14.51% 9.79% 8.11% 6.79% 2.91% -2.21% Other Income 40.63 34.80 26.10 14.76 12.84 12.99 16.29 12.25 14.39 6.77 5.85 Interest 1.46 1.20 0.63 0.95 1.09 1.14 0.00 0.00 0.00 0.00 0.00 Depreciation 39.99 14.94 16.26 16.95 20.13 18.58 14.92 14.74 15.83 17.43 15.28 PBT 156.36 203.11 174.33 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 Tax 40.62 58.03 34.81 21.44 33.79 41.76 18.22 17.89 15.45 0.50 0.00 Tax Rate 25.98% 26.43% 25.96% 25.82% 26.59% 36.64% 25.07% 40.84% 43.52% 8.68% 0.00% PAT 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 PAT before Minority Interest 115.74 161.51 99.29 61.60 93.30 72.21 54.45 25.91 20.05 5.26 -20.84 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 6.74% 12.47% 9.90% 7.65% 11.47% 8.68% 7.48% 4.54% 3.69% 0.93% -4.03% PAT Growth -28.34% 62.66% 61.19% -33.98% 29.21% 32.62% 110.15% 29.23% 281.18% - EPS 46.30 64.60 39.72 24.64 37.32 28.88 21.78 10.36 8.02 2.10 -8.34

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 711.92 588.69 511.39 456.17 364.44 300.80 246.93 222.87 156.01 150.76 Share Capital 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 Total Reserves 703.63 581.12 504.44 449.58 357.85 293.70 239.85 216.22 151.01 145.76 Non-Current Liabilities 97.83 68.99 73.63 44.60 44.13 22.75 109.73 88.68 38.96 1.02 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 116.30 85.97 84.91 50.50 49.47 46.11 142.28 128.90 37.70 0.00 Current Liabilities 467.15 484.40 392.30 373.43 367.10 267.60 218.67 202.05 234.05 259.82 Trade Payables 196.51 227.88 190.44 178.37 209.72 168.20 127.20 87.66 94.63 111.27 Other Current Liabilities 110.53 111.95 94.23 82.58 71.06 54.38 39.41 69.84 121.08 111.60 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Short Term Provisions 160.11 144.57 107.63 112.48 86.32 45.02 52.06 44.55 18.33 36.95 Total Liabilities 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.60 Net Block 66.68 68.86 74.49 80.96 71.53 74.83 75.46 86.84 97.36 100.99 Gross Block 187.13 179.12 168.83 159.78 132.84 119.83 105.85 102.57 203.76 191.44 Accumulated Depreciation 120.45 110.26 94.34 78.82 61.31 45.00 30.39 15.73 106.40 90.46 Non Current Assets 234.16 206.14 212.00 185.51 193.49 177.81 242.69 250.34 161.95 148.33 Capital Work in Progress 0.27 1.33 2.20 4.02 24.24 6.90 3.57 4.81 6.31 12.21 Non Current Investment 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 167.21 135.95 135.31 100.52 97.71 95.83 163.39 158.27 57.68 34.55 Other Non Current Assets 0.00 0.00 0.00 0.01 0.01 0.25 0.27 0.42 0.61 0.59 Current Assets 1,042.74 935.94 765.32 688.69 582.18 413.34 332.64 263.26 267.07 263.26 Current Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 227.88 190.21 140.22 159.80 165.15 118.10 113.15 57.71 76.73 86.13 Sundry Debtors 153.13 107.52 85.89 85.19 83.21 79.75 54.63 43.00 83.14 42.77 Cash & Bank 505.84 500.48 448.46 352.35 252.52 173.30 125.92 115.58 76.83 25.08 Other Current Assets 155.89 13.56 12.64 14.05 81.30 42.19 38.94 46.97 30.37 109.27 Short Term Loans & Adv. 142.66 124.17 78.11 77.30 61.45 29.25 30.87 23.43 20.22 107.46 Net Current Assets 575.59 451.54 373.02 315.26 215.08 145.74 113.97 61.21 33.03 3.44 Total Assets 1,276.90 1,142.08 977.32 874.20 775.67 591.15 575.33 513.60 429.02 411.59

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 27.87 58.29 100.80 104.78 87.42 54.98 8.79 38.10 56.99 -45.70 PBT 219.54 134.10 83.04 127.09 113.97 72.67 43.80 35.50 5.76 -20.84 Adjustment -7.07 -4.80 9.66 14.20 9.75 7.62 3.39 14.61 12.11 8.58 Changes in Working Capital -128.17 -30.19 32.89 -3.95 -2.66 9.81 -34.25 -0.24 42.09 -32.58 Cash after chg. in Working capital 84.30 99.11 125.59 137.34 121.06 90.10 12.94 49.87 59.97 -44.83 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -56.43 -40.82 -24.79 -32.56 -33.64 -35.12 -4.15 -11.77 -2.98 -0.87 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 21.74 18.11 4.74 173.03 -170.80 4.28 -9.36 0.25 -3.61 -18.64 Net Fixed Assets -6.95 -9.42 -7.23 -6.72 -30.35 -17.31 -2.04 102.69 -6.42 -24.59 Net Investments 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Others 28.69 27.53 11.97 179.75 -140.45 21.59 -7.32 -102.44 2.81 5.95 Cash from Financing Activity -44.38 -24.48 -9.46 -8.97 -6.36 0.00 0.00 0.00 -0.51 0.00 Net Cash Inflow / Outflow 5.23 51.92 96.08 268.84 -89.74 59.26 -0.57 38.35 52.87 -64.34 Opening Cash & Equivalents 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33 87.68 Closing Cash & Equivalent 505.57 500.34 448.42 352.34 83.50 173.24 113.98 114.55 76.20 23.33

Financial Ratios

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 283.45 234.45 203.78 181.83 145.14 119.48 97.94 88.49 62.41 60.30 ROA 13.35% 9.37% 6.65% 11.31% 10.57% 9.34% 4.76% 4.25% 1.25% -5.04% ROE 24.95% 18.13% 12.78% 22.83% 21.83% 20.03% 11.12% 10.63% 3.43% -12.93% ROCE 33.94% 24.49% 17.36% 31.24% 34.61% 26.53% 18.65% 18.74% 3.76% -12.93% Fixed Asset Turnover 7.11 5.79 4.93 5.58 6.58 6.45 5.49 3.58 2.88 2.91 Receivable days 36.53 35.03 38.57 37.62 35.75 33.67 31.15 41.96 40.32 33.27 Inventory Days 58.60 59.85 67.64 72.59 62.15 57.95 54.51 44.72 52.15 63.23 Payable days 131.27 214.92 220.48 246.52 99.66 91.40 73.21 75.53 75.14 85.66 Cash Conversion Cycle -36.14 -120.04 -114.26 -136.32 -1.76 0.22 12.45 11.15 17.33 10.84 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 183.95 213.86 88.41 117.60 100.97 0.00 0.00 0.00 0.00 0.00

Top Investors:

nippon life india trustee ltd-a/c nippon india small cap fund(various schemes)

tejas b. trivedi

shivani t. trivedi

prashant jain

investor education and protection fund (iepf)

Annual Reports:

News Update:

AstraZeneca Pharma gets permission to import for sale and distribution of Benralizumab
30th May 2025, 10:00 AM

Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis
Read More
Astrazeneca Pharma India receives approval to import for sale and distribution of Osimertinib Tablets
29th May 2025, 12:50 PM

The company has received permission from the CDSCO to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication
Read More
AstraZeneca Pharma surrenders marketing authorisation of prostate cancer treatment drug in India
15th Apr 2025, 15:30 PM

The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023
Read More
AstraZeneca Pharma gets nod to import Osimertinib Tablets 40 mg & 80 mg
5th Apr 2025, 15:52 PM

The receipt of this permission paves way for the marketing of Osimertinib Tablets 40 mg & 80 mg in India for the specified additional indication
Read More

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update:

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Standalone Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

Annual Reports:

News Update: